FutureCast | Time to Reboot Biotech

RApport’s FutureCast returned yesterday with a vibrant roundtable discussion about the health of the biotech industry and prospects for a recovery from the last two brutal years. 

If any of that sounds familiar, you might have already read the ​“Time to Reboot Biotech” article that we published just before the JPM conference. We wanted to give one of our most widely-read pieces some air time with a few hundred of our subscribers — who as you’ll see, weren’t shy about chiming in during the discussion (sadly the replay won’t show the constant Q&A taking place in the live-chat).

The panel also previewed one more financial analysis we just completed that contradicts a recently emerging conventional view of how to look for signals of a recovery. (It’s not in the Reboot article — but we’ll get to it, so stay tuned!)

Please click here for important RA Capital disclosures.